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expensive and time intensive. For example, 
the 2-year rat carcinogenicity study can 
cost up to $4 million and more than 500 
animals for a single chemical,[1,2] and yet, 
will require follow-up experiments in a 
separate set of animals to understand the 
toxicokinetics of the response and under-
lying mechanisms of toxicity. With the 
introduction of thousands of new chemi-
cals into the market every year that require 
immediate regulatory evaluations, and exu-
berant costs associated with the traditional 
animal testing, the path forward for the 
toxicological community is to find animal 
alternatives that will reduce or replace 
animal testing while enabling the genera-
tion of high quality scientific information 
relevant for assessing human health risks 
associated with chemical exposure.[3]
The situation with respect to assessing 
hazards and risks of exposure to nano-
materials (NM) is not different and can be 
perceived as even more complex than for 
chemicals. NM are engineered materials 
with a size range in the nanoscale (1 to 100 nanometers). The 
European Commission defines a NM as “a natural, incidental 
or manufactured material containing particles, in an unbound 
state or as an aggregate or as an agglomerate and where, for 
Faster, cheaper, sensitive, and mechanisms-based animal alternatives are 
needed to address the safety assessment needs of the growing number of 
nanomaterials (NM) and their sophisticated property variants. Specifically, 
strategies that help identify and prioritize alternative schemes involving 
individual test models, toxicity endpoints, and assays for the assessment of 
adverse outcomes, as well as strategies that enable validation and refinement 
of these schemes for the regulatory acceptance are needed. In this review, two 
strategies 1) the current nanotoxicology literature review and 2) the adverse 
outcome pathways (AOPs) framework, a systematic process that allows the 
assembly of available mechanistic information concerning a toxicological 
response in a simple modular format, are presented. The review highlights 1) 
the most frequently assessed and reported ad hoc in vivo and in vitro toxicity 
measurements in the literature, 2) various AOPs of relevance to inhalation tox-
icity of NM that are presently under development, and 3) their applicability in 
identifying key events of toxicity for targeted in vitro assay development. Finally, 
using an existing AOP for lung fibrosis, the specific combinations of cell types, 
exposure and test systems, and assays that are experimentally supported and 
thus, can be used for assessing NM-induced lung fibrosis, are proposed.
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1. Introduction
Current chemical hazard and risk assessment, and regula-
tory decision-making hinges on animal testing, which is both 
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50% or more of the particles in the number size distribution, 
one or more external dimensions is in the size range 1–100 nm”. 
NM exhibit size associated properties not observed or enhanced 
properties compared to the same material in its bulk or macro 
size form.[4,5] With their small size, particle number density 
and surface area per unit mass increase, which play an instru-
mental role in their transport, fate, and reactivity in different 
biological and environmental surroundings, and so are consid-
ered the important attributes of toxicity exerted by some such 
as insoluble and poorly soluble NM.[6–8] Additional associative 
physico-chemical properties such as chemical composition, sur-
face coatings, band gap, solubility, surface charge, and geometry 
influence their behavior in biological systems, resulting in an 
altered exposure, biokinetics as well as, relatively, a varied bio-
logical reactivity and toxicity.[9–11] Thus, in essence, a single NM 
of a particular chemical composition may be produced in a wide 
range of sizes with diverse surface properties and shapes, each 
exhibiting unique abilities that may impact, either negatively or 
positively, biological and environmental systems. From a toxi-
cological perspective, this poses many challenges as it would 
mean that each property variant of any NM may require a sepa-
rate safety assessment unless grouping of NM or feasibility of 
read-across can be demonstrated. If the existing animal toxicity 
testing strategies were used to complete the safety evaluations 
of the first generation NM already in commerce, approximately 
more than fifty years and billions of dollars will be required.[12] 
With the increasing sophistication of new generations of NM, 
and the associated availability of advanced materials,[13] the 
resources required for traditional safety assessments (i.e., 
animal testing) will no doubt increase significantly, making it 
imprudent to embark on such an endeavor.
In the last decade, the regulatory toxicology landscape has 
witnessed fundamental changes in strategies and approaches to 
substance safety testing, which promote the adoption of animal 
alternatives. It is posited that the in vitro and in silico models 
pose the most advantageous alternatives to the previously 
renowned “gold standard” animal testing strategies. Considering 
that the field of nanotoxicology is nascent and new compared to 
chemical toxicology, it is better placed to embrace the opportu-
nity and root itself predominantly on animal alternatives.[14]
Alternative methods and approaches have always existed and 
have been successfully applied in drug discovery; however, have 
witnessed endorsement in toxicology and extensive research 
investments for evaluating their applications to regulatory 
assessments only recently, especially following the publication 
of the National Research Council’s “Toxicity Testing in the 21st 
Century: A Vision and a Strategy” document.[3] Although lim-
ited, more than a handful of in vitro alternatives are available 
that have undergone formal validation, for which internation-
ally harmonized protocols and Organisation for Economic Co-
operation and Development (OECD) test guidelines (TGs) are 
available. These in vitro assays are in use for testing chemical-
induced adverse outcomes (AOs) such as genotoxicity/mutagen-
icity, skin sensitization, skin corrosion, eye irritation, and acute 
toxicity, among others. Several other in vitro test systems and 
assays are being evaluated toward acceptance as recognized and 
validated test methods for use in chemical testing and inclusion 
in regulatory decision making (https://tsar.jrc.ec.europa.eu/). 
However, these assays require further modifications before 
their application to NM testing. Although NM-specific hazards 
are not anticipated, NM are expected to cause hazards that may 
not be routinely targeted for regulatory assessments.[14] For 
example, inhalation toxicity is one of the primary concerns for 
NM exposure and validated alternatives to in vivo pulmonary 
toxicity tests are not currently available. Similarly, due to their 
particulate form, AOs similar to those induced by ambient 
air particulate matter are anticipated following NM exposure, 
which mainly involves the cardiopulmonary system.[5,15] How-
ever, cardiovascular toxicity is not routinely assessed in regula-
tory toxicology. Thus, within the existing framework of toxicity 
testing, in addition to some modifications to the established 
strategies, approaches, tools, and assays, and design and devel-
opment of novel test systems as applicable to NM testing, is 
also imperative. Yet, it is undecided as to what endpoints and 
which in vitro assays are relevant to achieve this important step 
in risk assessment of NM, as well as the progression and adop-
tion of alternative models for toxicology testing.
Previously, in a review by Halappanavar et. al.,[16] a broad 
overview of the adverse outcome pathways (AOP)/s, a descrip-
tion of why AOPs of relevance to NM are required, and spe-
cific AOPs of relevance to inhalation toxicity of NM that are 
currently under development were described. Furthermore, 
the authors constructed a network using the five linear AOPs 
outlining the putative mechanisms of NM-induced pulmonary 
toxi city and highlighted shared molecular initiating events 
(MIEs) and key events (KEs) across these AOPs. Authors used 
the AOP173 for lung fibrosis as a basis to present a putative 
AOP-informed tiered testing strategy that can be used for 
screening pro-fibrotic NM and for the prioritization of NM that 
potentially require further testing by complex in vivo models.
The present review article harnesses what was already estab-
lished in the previous review article by Halappanavar et. al.,[16] 
and builds on it further. In addition to briefly describing the AOP 
framework and its role in the design and development of targeted 
in vitro assays of relevance to the human health risk assessment 
(HHRA) of NM, the present review article 1) highlights the most 
commonly assessed and reported in vivo and in vitro ad hoc 
endpoints in nanotoxicology from the nanotoxicology database 
consisting of ≈30  000 publications, the discrepancies in what 
is assessed in vivo versus in vitro, the available OECD TGs for 
inhalation toxicity and the KEs targeted in these guidelines, and 
how the ad hoc endpoints reported in the literature can support 
targeted in vivo response-relevant in vitro assay development 
and 2) provides specific details on shared KEs derived from the 
network of inhalation toxicity AOPs, for consideration in in vitro 
test design. With the continued focus on inhalation toxicity of 
NM (as inhalation is one of the primary routes of exposure and 
adverse effects of lung exposure are most frequently assessed 
and reported for NM),[17] using the AOP network built in Halap-
panavar et al.,[16] the review will describe in detail the most recur-
ring or shared KEs in the AOPs of inhalation toxicity of NM and 
summarize alternative assays that are currently available for their 
measurement. Also, the review describes in detail, the specific 
cell types, endpoints, assays, exposure systems, and specific bio-
markers that can be anchored to the AOP173 for lung fibrosis 
and used for screening and assessing fibrogenic NM.
While the previous review article focuses on role of AOPs 
in nanotoxicology broadly, the present article presents select 
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AOP-informed in vitro alternatives and how they can be used 
in combination to generate the data required for assessing pro-
fibrotic NM. Finally, some considerations for validation and 
refinement of cell based in vitro alternatives are also discussed.
2. Current Nanotoxicology Literature: Most 
Frequently Reported Biological Endpoints and 
Their Applicability to In Vitro Cell-Based Assay 
Development
Most in vitro tests are conducted with an objective of under-
standing the underlying mechanisms of a substances’ toxicity. 
Thus, a vast majority of in vitro data available in the literature 
is not generated, interpreted or reported with a focus of sup-
porting regulatory functions or decision making.[18] The same 
can be said for the specific in vitro models used in toxicology 
testing. Nonetheless, some of in vitro methods can serve as tar-
geted approaches for specific toxicity endpoint testing to sup-
port the safety assessment of chemicals and NM.
In order to explore what is available in literature, or employed 
in terms of in vitro tests and identify relevant endpoints for 
in vitro testing, the nanotoxicology literature landscape was 
assessed using the Swiss-VCI database (supported by the Swiss 
FOPH and the German Chemicals Industry Association (VCI, 
Verband der Chemischen Industrie e.V.). The Swiss-VCI data-
base was primarily established for the purposes of evaluating the 
potential health, exposure, and environmental effects of NM,[19] 
consisted of 1878 studies published between 2009 and May 2013 
constituting 2598 datasets reporting on both in vivo and in vitro 
endpoints. The datasets reported on 100 biological endpoints 
(23 in vivo and 77 in vitro), for 110 different NM including 
Silver, cerium oxide, copper oxide, multi-walled carbon nano-
tubes (MWCNT), single-walled carbon nanotubes, titanium 
dioxide, zinc oxide, and their property variants among others. 
A total of 203 in vitro cell culture models from nearly 50 tissue 
types were included and assessed. In vivo studies described dif-
ferent animal species including rats, mice, xenopus, daphnia, 
and others. Most studies investigated and reported on mul-
tiple endpoints. Next, the endpoints as reported by the authors 
of the specific studies within the publication database were 
chosen to generate a list of biological endpoints. This list was 
then then analyzed for the frequency of how often a reported 
biological endpoint was investigated in all studies, separately 
for in vitro and in vivo experiments. The results showed that 
cell death was investigated 1431 times, chemokines/cytokines 
were investigated 607-times, etc. These specific numbers, that 
is, the number of times each of the 23 in vivo endpoints and 
the 77 in vitro endpoints were assessed, were transferred to the 
freely available program “wordle” (http://www.wordle.net/com-
pose) and each endpoint title was presented in the letter size, 
which is directly proportional to the frequency of its appearance 
in the studies. It is important to note that the words chosen for 
computing were picked directly from the studies in the database 
and represent the way in which the measured endpoints and 
results are reported. The results summarized in Figure 1 shows 
that in vivo, histopathology (192 times assessed) was the most 
assessed endpoint followed by body weight (78 times), survival 
(76 times), hematological alterations (61 times), liver toxicity 
(54 times), development (40 times), embryotoxicity (37 times), 
and kidney toxicity (30 times). Lung toxicity, heart toxicity, 
spleen toxicity, and hemolysis were also assessed but in fewer 
studies (25 times). On the other hand, in studies involving in 
vitro endpoints (Figure 2), cell death was the most commonly 
assessed endpoint and reported with 1431 mentions, followed 
by formation of reactive oxygen/nitrogen species (ROS/RNS, 
980 times), cellular membrane integrity (629 times), and altered 
expression of chemokines/cytokines (607 times). The other fre-
quently assessed in vitro responses or endpoints included DNA 
strand breaks, formation of oxidative products, cell number of 
infiltrated immune cells, anti-oxidative response, specific gene 
expression, depletion of glutathione, cell growth, and micro-
nuclei formation (from 128 times to 274). The results provide a 
high level summary of what endpoints and how were the end-
points reported in these studies in the database; however, it is 
acknowledged that granularity with respect to the specific type 
of measurements were not consistently reported. For example, 
hematological alterations included several different organ spe-
cific toxicity markers which could be associated with different 
tissues including liver, lung, heart, and kidney. Similarly, in vitro 
cell death endpoint did not differentiate between the type of 
death (e.g., apoptosis or necrosis) and different events involved 
in cell death or different stages of cell death (e.g., mitochondrial 
Figure 1. Word computing results following outcome of in vivo assessment within the database analysis described by Krug et al.[19]
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dysfunction or increased cellular membrane permeability). 
This was determined to be the result of inconsistent ontology/
terminology used and lack of harmonized reporting standards in 
nanotoxicoloy. In recent studies by Halappanavar et al., a subset 
of the Swiss-VCI database consisting of 191 individual publica-
tions specifically reporting on NM-induced pro-inflammatory 
response and inflammation associated events, was analyzed in 
detail and attempts were made to harmonize the terminology. 
For example, inflammation response was generically reported 
in vitro as “cytokines and chemokine expression” or in vivo as 
“bronchoalveolar lavage fluid cell number” for lung inflamma-
tion or “inflammatory cells” for other tissue inflammation, such 
as liver or simply as “Interleukin (IL)-1”, “IL6”, etc. (the specific 
pro-inflammatory markers) both in vivo and in vitro studies.[20,21] 
Using some level of expert judgement, these reports were reor-
ganized and renamed as “altered expression of pro-inflamma-
tory mediators”, and recruitment of leukocytes’, the two generic 
characteristics of the inflammation process.[22] This allowed cat-
egorical grouping of the reported results in a biologically log-
ical manner and allowed identification of each endpoint, assay 
and specific biomarkers used to assess and report the various 
inflammation related responses. However, conducting such an 
analysis for all the publications in the large database of 11 000 
publications is beyond the scope of this review.
Regardless of the issues highlighted above, the results can 
be used to inform the prioritization or selection of in vivo 
responses for which in vitro endpoints may be designed. For 
example, the enriched in vitro endpoints in the database high-
light the most acknowledged modes of action for NM, which 
include oxidative stress paradigm (highlighted by the terms 
reactive oxygen species/nitrogen reactive species, formation of 
oxidative products, depletion of glutathione, and anti-oxidative 
response), inflammation (cytokines and cell number of infil-
trated immune cells), genotoxicity (strand breaks), and cell 
injury (cellular membrane permeability, membrane integrity, 
and cell death). Thus, in the short term, these individual in vitro 
endpoints reflecting the toxicity modes of action of NMs can be 
prioritized and targeted for further development. The in vitro 
endpoints with an established association to in vivo responses, 
for example, the endpoints associated with genotoxicity such as 
DNA strand breaks or mutagenicity should also be prioritized 
for further development.
However, the issues concerning the relevance and effec-
tiveness of the existing data in predicting in vivo toxicity still 
remains. The results of the word computing analysis clearly 
demonstrated a substantial discrepancy between what is 
assessed in vivo versus in vitro studies included in the  database. 
The discrepancy is probably due to the technical limita-
tion to assess the same endpoints in the two approaches. For 
instance, in animal experiments the cell specific response, 
that is, DNA strand break, is difficult to investigate, whereas 
in cell-based assays body weight or systemic effects can 
Figure 2. Word computing results following outcome of in vitro assessment within the database analysis described by Krug et al.[19]
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obviously not be assessed. Furthermore, it seemed that most in 
vivo studies involved organ or system toxicity endpoints (e.g., 
behavior, development, neuronal damage, toxicity of liver, heart, 
lung, kidney, and spleen) of relevance to regulatory purposes, 
whereas, in vitro studies mostly targeted a particular biolog-
ical process such as inflammation, genotoxicity, or cytotoxicity 
potentially reflective of organ toxicity in vivo. Although a wide 
variety of assays were identified for each endpoint or response 
assessed in in vitro studies, prospectively, the ability to trans-
late the in vitro data collected to understand in vivo toxicity was 
not evident. For example, the results of cytotoxicity assays were 
common to most in vitro studies in the database; however, it 
was not clear if the results can be related to in vivo toxicity. It 
is also important to note that despite the increased number of 
studies testing a certain endpoint (e.g., cytotoxicity), that this did 
not mean that the endpoint was, in fact, a toxicologically posi-
tive result (i.e., it caused an effect). At present, cytotoxicity may 
be regarded as information that may be required for the inter-
pretation of the readouts from other in vitro assays in the same 
experiment. In a majority of cases, the in vitro test system was 
not anchored to an in vivo response. Also, what was not clear 
from the literature findings is what do these in vitro tests pre-
dict in terms of the observed toxicity or AO in vivo and how well 
is the in vivo organ represented by an isolated single cell type or 
an advanced test system constituting multiple cell types in cul-
ture under simulated conditions? Resolution of these issues will 
require in-depth understanding of the underlying mechanisms 
of NM-induced toxicity or NM mode-of-action and identification 
of key biological events involved in the toxicity pathways.
In fact, from the research conducted to-date, the intricate 
biology, if only partially, of the NM induced response and asso-
ciated mechanisms of toxicity have been revealed for some NM 
(e.g., carbon nanotubes (CNT) and metal oxides).[23–26] This 
complex information can be meaningfully organized into an 
emerging concept of an AOP framework.[16,27,28] Positioned to 
help identify the most essential components of the NM toxicity 
mechanisms at the relevant biological organization (molecular, 
cellular, tissue, etc.), this approach will enable anchoring of the ad 
hoc in vitro measurements (e.g., inflammation, cytotoxicity, etc. 
as mentioned above) to an in vivo response that is critical for the 
occurrence of an adverse effect and thereby guide the design and 
development of targeted in vitro tools and assays for assessing 
the NM-induced in vivo response. In the following sections, we 
describe how mechanistic information organized in line with 
the AOP framework may be used to identify and define in vitro 
assays that are potentially useful for generating toxicological data 
required for NM safety assessment and regulatory decisions.
3. The Adverse Outcome Pathway framework
3.1. What are Adverse Outcome Pathways
AOPs allow systematic collection, organization, and simplistic 
presentation of the complex toxicological response identified 
in vivo in a linear and modular format.[29] The components of 
an AOP include: A MIE, defined as a biological event occur-
ring at the molecular level following exposure to substances; 
a series of KEs, defined as essential response events spanning 
the cellular, tissue, and organ levels of biological organization 
that are sequential, causal, and that connect the MIE with an 
eventual AO and an AO defined as the disease or the patho-
logical outcome of triggering a toxicity pathway, which are tar-
geted for regulatory decisions.[30] MIE and AO are specialized 
KEs and serve as anchors; a single MIE can result in multiple 
AOs or multiple MIEs may be linked to a single AO. There are 
no restrictions on the number of intermediate KEs involved in 
any AOP. The other important components or building blocks 
of an AOP are the key event relationships (KERs) that deter-
mine the quantitative aspects, such as toxicologically-orientated 
thresholds, dose-response of relationships shared between KEs, 
and the temporal dynamics. In other words, KERs describe the 
level and duration of engagement of an upstream KE required 
to trigger the activation of a downstream KE. AOPs allow inte-
gration of information from a wide variety of sources, that is, 
in silico, in vitro, and in vivo (animal and human epidemio-
logical) within a plausible framework, enabling elucidation 
of the complex mechanisms in simplified details. AOPs also 
provide a detailed account of the domain of applicability in 
terms of cross-species conservation of the mechanisms, and 
gender specific differences in response.[31–33] Another impor-
tant aspect of AOPs is that they are stressor-agnostic and thus 
allow for integration of toxicological information derived from 
a wide variety of diverse chemicals, NM as well as other types 
of stressors such as radiation. However, although AOPs are not 
chemical-specific, their application allows consideration of their 
biological plausibility, which includes elucidation of cause-
and-effect relationships, as well as identification of physical 
and chemical properties of the material that may induce devia-
tions in the toxicity mechanisms. Depending on the quality 
and quantity of data used to build any AOP, it can be putative, 
qualitative, semi-quantitative, or quantitative. There are many 
different approaches to developing AOPs and an AOP develop-
ment guidance has been established by the OECD[30,34] and a 
database of AOPs for various AOs of relevance to human health 
is available https://aopkb.oecd.org/. Current efforts within the 
field of nanotoxicology have focused on developing new AOPs 
or refining existing AOPs based on single or multiple model 
stressors. In addition, data mining approaches using high-
throughput and/or high-content information, such as omics 
data, for the identification of KEs or to support the develop-
ment of full AOPs has also been used for NM.[35–38]
3.2. Their Utility in Human Health Risk Assessment  
of Nanomaterials
Depending on the quality and quantity of data used in con-
structing AOPs, AOPs can have far-reaching application in the 
formal NM risk assessment process.[39,40] As stated above, the 
AOP framework allows collation and logical organization of a 
battery of experimental data from different sources and identi-
fication of essential biological events that are both physiologi-
cally and chemically plausible. By that, AOPs can help identify 
key data gaps concerning a stressor, an AO, or the associated 
mechanism, and thereby focus research priorities and resource 
investments. The putative, qualitative, or semi-quantitative 
AOPs can be used to identify available alternative methods, 
selection, and design and development of novel in vitro alter-
natives and, to support integrated approaches to testing and 
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assessment (IATA) principles[41–45]–—the guidance published 
by OECD[46] to standardize and evaluate IATA mentions six 
general principles that all IATA’s constitute, which include 
a defined endpoint, a defined purpose, a description of the 
underlying rationale, a description of the individual informa-
tion sources used, a description of how data from individual 
sources are processed, and a consideration of the known uncer-
tainties along with a description of the magnitude of each 
source of uncertainty.[47] When the available data for quantita-
tive risk assessment is insufficient, AOPs help identify the 
type of new data required. AOPs provide biological context for 
the selection of in vitro assays and inclusion of in vitro data 
derived from such assays in decision making.[48] MIE describes 
an initial point of interaction between stressors and the bio-
molecule, and thereby, link the structural features and chem-
istry of a stressor to a response. MIEs allow the development 
of predictive methods such as quantitative structure-activity 
relationship (QSAR) and, support chemical categorization and 
read across strategies. The intermediate KEs are as important 
as MIEs and used to identify and prioritize measurement end-
points and assays, as relevant to the biological organization, 
and in early screening tier assessments. Assays based on KEs 
have been successfully applied in early identification of hazards 
during the drug development and research, and in prioritiza-
tion of chemicals for further regulatory assessments. Quanti-
tative AOPs, which mathematically describe the complex dose, 
time, and response–response relationships shared between KEs 
and the AO, and the factors that modulate these relationships, 
enable quantitative prediction of probability of the AO occur-
rence or expected extent of the AO manifestation at a speci-
fied exposure level. Where exposure is characterized and the 
physico-chemical properties of the substance are identified, the 
quantitative AOPs facilitate formal and effective HHRA, aiding 
regulatory decision making.[40]
4. Strategic Use of Adverse Outcome Pathways 
in the Design and Development of In Vitro Cell-
Based Alternatives Relevant to Safety Evaluation 
of Nanomaterials
4.1. A Case Study of Inhalation Toxicity for Focused In Vitro 
Assay Development
Currently, a handful of AOP skeletons, or roadmaps clearly 
describing the underlying toxicological mechanisms following 
inhalation exposure to NM are available. These include AOPs 
for AOs of potential relevance to NM risk assessment and regu-
lation, and for which an AOP development proposal has been 
submitted or under review by the OECD Extended Advisory 
Group on Molecular Screening and Toxicogenomics (EAGMST) 
AOP committee (https://aopwiki.org/).[16] These AOPs are
• Lung fibrosis (including inflammation) (AOP173 (https://
aopwiki.org/aops/173): Substance interaction with lung 
resident cell membrane components leading to fibrosis, 
and NO ID: Substance interaction with lung epithelial and 
macro phage cell membrane leading to lung fibrosis)
• Lung emphysema (AOP1.25: Increased substance interaction 
with alveolar cell membrane leading to lung emphysema)
• Acute lung toxicity (AOP302: Lung surfactant function dis-
ruption leading to acute lung toxicity)
• Lung cancer (AOP303: Frustrated phagocytosis leading to 
lung cancer)
• Atherosclerotic plaque formation (AOP237: Cellular sensing 
of stressor leading to plaque progression)
Of these, only the AOP for lung fibrosis is fully developed 
and has undergone both internal and external reviews organ-
ized by the OECD EAGMST committee. It is important to note 
that as AOPs are developed according to the principles and 
guidance published by OECD,[30] the individual AOP titles are 
subjected to change; however, they can be looked up in AOP-
wiki using the unique AOP identification number associated 
with them (https://aopwiki.org/). The individual KEs identified 
in these AOPs can serve as the basis for the targeted in vitro 
assay development.
In a recent review published by Halappanavar et  al.,[16] 
each of these linear AOP roadmaps were examined for their 
interconnectivity and a network of AOPs representing the 
complexity of the respiratory biology perturbed by NM was 
described. Although none of the AOPs have been formally vali-
dated or endorsed by the OECD,[16] they can be used to inform 
the research and development priorities. The shared, or com-
monly occurring KEs in the network can be prioritized for the 
development of in vitro cell-based bioassays that can be used in 
tier-1 screening and assessment of NM.
Figure 3 is a modified AOP network presented in Halap-
panavar et  al.,[16] and shows how individual KEs in a single, 
linear AOP interact with KEs in other AOPs. A detailed anal-
ysis of the network showed a significant overlap between the 
KEs across the AOPs; however, the KE (biological events) titles 
were described using different words and terms, resulting in 
redundant KEs. The MIEs were largely non-specific and did 
not identify a specific NM target at the molecular level, rather 
described the NM-bio interactions in a broader sense involving 
different lung cell types, lung cell membrane components, 
and other biomolecules of the lung microenvironment. The 
NM-bio interaction could be physical, mechanical, receptor-
mediated, and/or binding to proteins. Even though NM may 
be in the molecular size range and capable of significantly 
influencing the functions of biomolecules in the surrounding 
environment, the major toxicity mechanisms identified to date 
do not specify the type of interactions or specific biomolecules 
involved in the nano-bio interaction. Among the KEs, KEs of 
inflammation process, including altered expression of (pro-)
inflammatory mediators and increased recruitment of leuko-
cytes, were common to greater than three AOPs in the network 
(Figure 3), respectively. However, similar to the MIE, inflamma-
tory KEs were broadly described and did not specify the main 
actors such as the specific (pro-)inflammatory mediators or 
inflammatory cell types involved. There was also a high degree 
of overlap between the KEs describing loss of alveolar capillary 
membrane integrity (common to three AOPs), and activation 
of T helper type 2 type response, fibroblast/myofibroblast pro-
liferation and extracellular matrix (ECM) deposition (common 
to two AOPs). In addition, events such as oxidative stress and 
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cytotoxicity were common to two AOPs. Oxidative stress was 
defined as an associative event (responsible for the exacerbation 
of a response but may not be deemed essential to be listed as 
a KE in the pathway) in two AOPs—AOP173 lung fibrosis and 
AOP1.25 lung emphysema, and was positioned as a KE in the 
AOP303 for lung cancer. The most highly connected KE was 
the “Increased, recruitment of (pro-)inflammatory cells” related 
to inflammation and the most central KE was “Loss of alveolar 
membrane integrity”, a tissue level KE reflecting tissue injury. 
From the network derived, it may be stated that NM-induced 
AOs have a similar origin, involve common KEs and that the 
eventual AO trajectory may be influenced by the NM property 
variations and, duration and time of exposure. The network 
analysis also suggested that certain NM may have the capacity 
to induce multiple AOs in a single exposure setting.
Albeit the lack of specificity, the shared KEs from the network 
can be used for identification and selection of in vitro endpoints 
for further development to support the first-tier testing strate-
gies for the purposes of screening and prioritization of NM. In 
fact, the individual AOP roadmaps and shared KEs can be used 
to anchor the ad hoc in vitro endpoints identified from the litera-
ture (Section 2), thereby enabling mechanistic interpretations of 
the data generated in the context of in vivo toxicity relevance. The 
other considerations for selection and prioritization may involve 
targeting of KEs, which have demonstrated in vivo relevance, 
which can be easily measured, and for which well established in 
vitro assays and methodologies already exist. Below, each shared 
KE from the network (Figure  3) are described in detail along 
with the endpoints available for measuring them.
4.2. Shared Key Events as the Basis for Potential Development 
of Animal Alternatives
Table 1 shows the most overlapping KEs from the network 
(common to more than two linear AOPs), the existing OECD[49] 
approved in vivo methods available (TGs 403, 412, and 413) for 
measuring these KEs, potential in vitro systems available, as well 
as listing ad hoc endpoints that are commonly measured in vitro 
to assess these KEs. It is evident that only a small fraction of the 
toxicity response pathway induced by NM, targeting mainly one of 
the early KEs and the end disease KE, is assessed in vivo and cur-
rently, there are no validated cell-based alternatives for the same.
4.2.1. Molecular Initiating Events Highlighting Types of  
Nanomaterials–Cell Interaction
The MIEs described in linear AOPs involve the interaction of 
NM with the outer cell membrane components or interfere 
Figure 3. Network of AOPs relevant to nanomaterials, highlighting KEs which show promise as screening targets for downstream toxicity. MIEs are labeled 
green and AOs are labeled in red. The KEs which are common to three or more AOPs are labeled purple. All other KEs are labeled grey. KERs are represented 
as arrows (adjacent KER: Solid; associative KER: Dashed; non-adjacent KER: Contiguous) and KERs associated with a particular AOP have the same color-
ation. Adapted under the terms of the Creative Commons Attribution 4.0 International License. (https://creativecommons.org/licenses/by/4.0/) Copy-
right 2020, The Author(s). Published by BioMed Central. For more details on network construction and individual AOPs contained in the network, refer to 
Halappanavar et al.[16]
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with the biomolecules in the surrounding medium (e.g., physi-
ological fluids, cell culture medium) in a way which has a direct 
impact on the tissue/cell response. Thus, for NM-relevant AOs, 
the term MIE may not always reflect a molecular level interac-
tion as required by its formal definition.[36] In the human lung, 
inhaled NM are first received in the bronchoalveolar lining fluid 
(BALF), where they are exposed to a complex mixture of lipids 
and proteins, known as lung surfactant. The secretions protect 
the host from pathogens and environmental threats, as well as 
contribute to the normal functioning of the lung. The binding 
of secretory proteins, for example, surfactant proteins, to NM 
results in their displacement via wetting forces, altering their 
function, and can impact the surfactant layer required for the 
maintenance of surface tension in the alveolar region,[50–52] ulti-
mately resulting in an acute respiratory distress and inhalation 
toxicity (AOP302). Mechanical interaction of high aspect ratio 
NM (HARN) such as CNTs with cells is shown to pierce the cell 
membrane resulting in frustrated phagocytosis, cellular injury, 
and death,[53,54] which is associated with multiple AOs including 
lung fibrosis (AOP173, AOP NO ID), lung cancer (AOP303), 
lung emphysema (AOP1.25), and even a systemic AO involving 
the cardiovascular system[55] (AOP237, atherosclerotic plaque 
formation).[5,56] The NM are also suggested to induce foreign 
body reaction in the host cells. The danger associated molecular 
patterns (DAMPs) such as the cellular debris and cytokines or 
alarmins released from the injured or dying cells act as ligands 
to the pattern recognition receptors present on the surface of 
the resident epithelial, alveolar macrophage, and other lung 
immune cells, and consequently, activating them.[57] Insoluble 
NM adsorbed with opsonins including immunoglobulins and 
serum proteins also serve as ligands to the receptors on the 
macrophage cell surface, triggering the immune response cas-
cade. In many instances, multiple types of interactions can be 
initiated simultaneously by a single NM. Thus, the broad MIE 
involving NM-bio interaction at large is critical for governing 
the cellular response to NM and it is the determinant of the 
toxicity trajectory toward an AO; however, the MIE is not tar-
geted for assessment in vivo in acute, sub-acute, or sub-chronic 
inhalation exposure studies and not captured in the OECD TGs 
403, 412, and 413.[58]
As such, NM-bio interaction per se is scarcely investigated in 
nanotoxicological studies and some examples of endpoints used 
for the measurement include the assessment of lipid-NM and 
protein-NM corona[59,60] which does, however, not consider the 
direct nano-bio interaction at the molecular level. However, the 
MIE is routinely measured indirectly by assessing the down-
stream consequences of NM-bio interactions. For example, the 
release of DAMPs (alarmins, IL1α, and IL1β) in the extracel-
lular medium, expression changes in effector genes and pro-
teins downstream of an activated receptor pathway, and cellular 
uptake of NM, are some of the endpoints employed to indi-
rectly measure the MIE activation. Although not routinely used, 
sophisticated cell-free microscopic methods such as fluorescent 
resonance energy transfer microspectroscopy are employed for 
detecting NM interacting with lipid layers in real time. The jus-
tification for selecting specific endpoints can be derived from 
the NM physical-chemical property alerts. For example, for 
soluble NM or HARN, in addition to DAMP release, the spe-
cific measurements could include lysosomal enzyme release 
(cathepsin B), lysosomal membrane destabilization, and release 
of (pro-)inflammatory cytokines. Some endpoints such as lyso-
somal destabilization and cellular uptake may be considered 
as MIEs for certain NM. Another possibility to study NM-cell 
interaction is to assess visually or quantitatively the interaction 
of NM with cells and cellular internalization. A battery of tech-
niques is available to detect and to quantify metals, metal oxides, 
magnetic, fluorescent, as well as electron dense NM, including 
inductively coupled plasma atomic emission spectroscopy, flow 
Table 1. Summary of shared KEs and, available OECD recommended in vivo assays and potential in vitro endpoints and assays available for meas-
uring them.
Overlapping KEs OECD in vivo inhalation toxicity assaysTG 




with the resident cell membrane 
components.
Expression changes in alarmins, 
lysosomal enzymes, receptor pathway 
activation, cellular uptake, and  
lysosomal destabilization assays
NM–protein, NM–lipid interactions, 















tory and profibrotic mediators
BALF parameters—
–Lactate dehydrogenase
–Total protein or albumin
–Total leukocyte count, absolute cell 
counts, and calculated differentials for 
alveolar macrophages, lymphocytes, neu-
trophils, and eosinophils.
Histology
Resident immune cell mobilization—
histology Ex Vivo
KE—Increased, recruitment of 
proinflammatory cells
Expression changes in proinflamma-
tory and profibrotic mediators





–Total protein or albumin
Lung burden—persistence of NM
TEER
Cell death/cytotoxicity
AE/KE—ROS synthesis ROS levels
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cytometry, light, and electron microscopy.[61,62] Thus, a number 
of endpoints are available that assess indirectly the MIE of 
the NM-bio interaction. In a recent study by Jagiello and col-
leagues,[63] transcriptomic responses following exposure to 
MWCNTs that corresponded with the inflammatory KEs of the 
AOP173, were employed to build a QSAR model to identify the 
structural aspects of MWCNTs that may be responsible for ini-
tiating the lung inflammatory response. The study identified 
several individual gene (molecular) targets for MWCNT interac-
tion, which may be used to refine endpoints and specific assays 
for the MIE measurement.
4.2.2. Key Events of Inflammatory Process in General
Inflammation is the organism’s response to threats and insults 
such as pathogens, (bacterial) infection, trauma, and hypersen-
sitivity. Inflammation is a complex and broad act involving sev-
eral events at the molecular, cellular, and tissue levels, played 
by different actors in a substance, cell, tissue, or otherwise spe-
cies-specific manner. However, the process of inflammation is 
characterized by the three cardinal events “Tissue resident cell 
activation, ‘Increased pro-inflammatory mediators”, and “Leu-
kocytes recruitment/activation”, of which the latter two are fre-
quently reported events following NM exposure.[64,22]
Altered Expression of (Pro-)Inflammatory Mediators: (Pro-)
inflammatory mediators are the chemical and biological 
molecules that initiate and regulate inflammatory reactions. 
They include cytokines, chemokines, and growth factors (cell-
derived), and vasoactive amines, complement activation prod-
ucts, and others (blood derived). A variety of them are secreted 
during innate and adaptive responses to inflammogens, inde-
pendent of gender or developmental stage influences but in a 
species, tissue, or the exposure specific manner. A large number 
of NMs induce expression of cytokines and chemokines in the 
lungs of rodents exposed via inhalation[65–68] or in vitro in lung 
cells exposed under submerged conditions.[69,70] Inflammation 
induced by many NMs such as metal oxide nanoparticles and 
CNTs is characterized by continual release of (pro-)inflammatory 
cytokines and ROS, which is attributed to their pathogenicity 
potential.[71] These modulators can be grouped based on the cell 
type that secrete them and also based on the type of immune 
response they trigger, which is one of the criteria used in their 
selection for the KE measurement. The other factors that influ-
ence specific selection of mediators for investigation vary based 
on the expertise of the lab, cell types studied, and the avail-
ability of resources. Expression changes in single or select set 
of (pro-)inflammatory mediators is the routine endpoint used to 
measure this KE both in vitro and in vivo, and involves simple 
assays such as the single or multiplex quantitative real time 
polymerase chain reaction (PCR) and enzyme linked immuno-
sorbent assay (ELISA) or flow cytometry techniques that enable 
detection of intracellular mediator proteins. This KE is not speci-
fied in the OECD TGs for inhalation toxicity assessment.
Increased Recruitment of Leukocytes: (Pro-)inflammatory leu-
kocytes (dendritic cells, monocytes/macrophages, and neutro-
phils) are circulating white blood cells, derived from the bone 
marrow, that are recruited to the site of infection in lungs, upon 
sensing or recognition of danger, to clear the invading threats, 
pathogens, or toxic substances.[72] They differentiate into 
mature immune cells and are categorized based on their phe-
notype and activation status, and subsequently their size, the 
type of receptors they carry on their surface, and their ability 
to differentiate following external or internal stimulus such 
as increased expression of cytokines. Activated immune cells 
secrete a variety of (pro-)inflammatory mediators, which propa-
gate the immune signaling and response, which when not con-
trolled, leads to chronic inflammation and tissue injury. Thus, 
the two shared KEs of inflammation act in a positive feedback 
loop mechanism and fuel the (pro-)inflammatory environment. 
Increased neutrophil number in BALF is the predominantly 
assessed and reported endpoint for NM exposure via inhalation 
in vivo. All known inflammogenic NM induce the recruitment 
of inflammatory cells to the site of injury in lungs. The extent of 
this recruitment depends on the exposure doses, duration, and 
the properties of the specific substance, and thus, is an excel-
lent endpoint to determine the potency of NM. This endpoint 
is routinely measured in vivo and a detailed guidance on how 
to measure this endpoint is outlined in TGs 412, 403, and 413; 
however, it cannot be assessed in vitro. Instead, the KE “Altered 
expression of pro-inflammatory mediators” is used as a proxy 
in vitro. A suit of (pro-)inflammatory mediators specific to cell 
types are assessed using the same techniques mentioned above 
(qRT-PCR, ELISA, flow cytometry, and immunohistochemistry) 
in different cell culture models. In vivo measurement of leuko-
cyte influx is a signatory of the clinical manifestation of inflam-
mation, it lacks specificity in discriminating the material or 
mode-of-action specific responses. The expression, abundance, 
and activity measurements of specific pro-inflammatory media-
tors enable identification of specific pro-inflammatory mecha-
nisms involved in the response.[5]
4.2.3. Key Event of Tissue Injury, Loss of Alveolar-Capillary Tissue 
Membrane Integrity
The alveolar-capillary tissue membrane (ACM) is the gas 
exchange surface of the lungs acting as a barrier between air 
and the blood circulation. The alveoli are lined by squamous 
cells, the alveolar type I epithelial cells which cover about 
95% of the surface and share a basement membrane with the 
endothelial cells covering the pulmonary capillaries, and also 
contain alveolar type II epithelial cells, which secrete lung sur-
factant (surface active agent) to prevent alveolar collapse.[73] 
The structural barrier between air and blood is reduced to a 
mean arithmetic thickness of 2.2  µm or thinner tissue layers 
in the alveoli.[74] ACM is the primary target for all inhalation 
toxicants and is subjected to injury constantly. Extensive injury 
to ACM resulting in the loss of its barrier integrity presents a 
“point of no return” situation for the tissue. The loss of ACM 
integrity and increased membrane permeability leads to efflux 
of protein-rich fluid into the peribronchovascular interstitium 
and the distal airspaces of the lung, altered fluid transport via 
disturbances caused in Na channels or malfunctioning Na+/
K+ATPase pumps, loss of the surfactant layer (particularly sur-
factant protein D), as well as altered expression of adhesion 
molecule-1 (ICAM-1) and many more markers of decreasing 
lung compliance arising from the lost integrity of ACM.[75] 
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Chronic inflammatory conditions and oxidative stress con-
tribute to ACM loss, which is further influenced by the phys-
ico-chemical properties of NM and their exposure regime. The 
compromised ACM integrity in vivo is measured by measuring 
total protein or total albumin content in BALF fluid such as 
recommended in the OECD TGs 403, 412, and 413. In the case 
of NM, the lung burden of NM is suggested to assist in deter-
mining the potential extent of injury.
In vitro, studies often assess the altered expression of (pro-)
inflammatory mediators, increased ROS synthesis, or oxida-
tive stress and cytotoxicity, interplay between which is sug-
gested to induce cell injury, reflective of tissue injury, or loss 
of ACM in vivo (Halappanavar[20]). As such, cellular viability or 
cytotoxicity assays are the most commonly used endpoints to 
assess the leaky or compromised cell membrane. The tissue 
barrier integrity in lung cell models can be assessed if the 
lung cells are grown on permeable supports enabling the cul-
ture medium to be separated on either side of the cultured 
epithelium.[76] Trans-epithelial electrical resistance (TEER) is 
an accepted quantitative technique that measures the barrier 
integrity in cell culture models of endothelial and epithelial cell 
monolayers. They are based on measuring ohmic resistance 
or measuring impedance across a wide range of frequencies. 
Another method to test the epithelial integrity is to measure 
the permeation of the lung cell barrier by a paracellular marker 
(e.g., 14C-mannitol, fluoresceine, or different dextrans) which 
can be characterized by the apparent permeation co-efficient. 
Finally, epithelial/endothelial cultures can be screened for 
tight junction or adherens junction proteins using a variety of 
methods, such as real-time PCR, western blot, immune histo-
chemistry, and immunofluorescence (for a review see Rothen- 
Rutishauser et al.).[77]
4.2.4. Key Event Representing Oxidative Stress, Formation  
of Reactive Oxygen Species
Oxidative stress mainly assessed by measuring the increase 
in total intracellular ROS levels is associated with cellular 
response to interaction of NM with surrounding cells. Acute 
increase in ROS, which is mainly benign, is generated by the 
surface reactivity of NM. The endogenous anti-oxidant capacity 
of cells renders protection from ROS induced acutely after 
exposure to NM, which is a DAMP that participates in the host 
defense mechanisms by sensing and signaling the presence of 
danger, and activating redox-sensitive processes. ROS is also 
generated by the metabolic activity of inflammatory phago-
cytes (commonly known as an “oxidative burst”) during the 
process of phagocytosis, which also serves to protect the host. 
However, repeated or persistent exposure to ROS-inducing NM 
results in persistent ROS generation, quickly depleting the cel-
lular anti-oxidant capacity and induction of oxidative damage to 
cells. If not resolved timely, ROS generated can contribute to 
other downstream events such as inflammation, cell death, and 
tissue injury, all of which can act in a positive feedback loop 
exacerbating the response toward pathological or toxicological 
consequences. In the AOP for lung cancer (AOP303), ROS syn-
thesis is associated with oxidative DNA damage leading to DNA 
mutations and carcinogenic transformations.
Oxidative potential of the particle surface is measured using 
acellular assays including 2′,7′dichlorofluorescin diacetate 
which has been widely used as a marker for oxidative stress[78] 
or use of carboxy-H2DCFDA oxidation inside cells as a fluores-
cence marker for ROS production. The latter can be used in in 
vivo (BALF) as well as in vitro experiments.[79] For metal oxide 
NM, energy levels of the conduction band (band gap) is used 
to identify the redox potential of the material. Measurement of 
increased ROS synthesis in cells, expression changes in genes 
related to pro-/anti-oxidative stress, activation of anti-oxidant 
canonical pathways, and oxidative damage of DNA, proteins, 
and lipids, are some of the endpoints routinely measured to 
assess this event in vitro.
Thus, there are several endpoints and specific assays cur-
rently available for investigating the occurrence of shared KEs. 
These measurements of shared KEs observed early in the AOPs 
can serve in tier-1 screening and guide the endpoint selection 
for investigation in the next tier. Thus, the shared KEs can be 
prioritized for the design and development of fit for purpose in 
vitro models and assays.
4.3. Advanced In Vitro Systems for Inhalation Toxicity Testing
It is important to note that none of the existing in vitro model 
or systems, in isolation or in combination, are complete in 
terms of their effectiveness in accurately recapitulating the 
complex human or animal lung responses to xenobiotic expo-
sure. The whole lung response includes proximal and distal or 
alveolar airway components, and signaling from mesenchymal, 
vascular, immune, neural, and other components of the tissue, 
which are not entirely mirrored in the available 2D or 3D cell 
culture models. However, the combination of in vitro models 
and systems proposed below offer real time monitoring of 
pathological responses under controlled environments, enable 
higher-throughput assessment capacity and can be reproduced, 
which is a critical advantage over clinical or animal studies. As 
the field ploughs through with advancements in technology and 
deeper knowledge of the biology, more complexity is expected 
to be added to these systems to bring them as close to the lung 
environment as possible.
4.3.1. Exposure Models
One of the important considerations for design and develop-
ment of an optimal inhalation toxicity testing system for NM 
is the mode of exposure. Historically, lung toxicity models 
including single cell type cultures, advanced in vitro culture 
models of multi-cell types, as well as that of precision cut 
tissue slices due to the cost of their resource as well as the 
expertise and time, have been exposed under submerged con-
ditions; That is, where cells are exposed to NM pre-suspended 
in relevant exposure medium. However, in order for bio-NM 
interaction to occur, for some NM, lung cells may have to be 
exposed to an aerosol. The air–liquid interface (ALI) culture 
method has seen significant developments as is recommended 
from many experts for this purpose.[80–82] In addition to the 
possibility to culture lung cells at ALI a number of different 
Small 2021, 2007628
2007628 (11 of 20)
www.advancedsciencenews.com
© 2021 Her Majesty the Queen in Right of Canada. Small published by Wiley-VCH GmbH. 
Reproduced with the permission of the Minister of Health Canada
www.small-journal.com
(commercially) available ALI exposure systems are avail-
able.[83] Such ALI exposure systems also have the advantages 
that the cells are directly exposed to the NM aerosol allowing 
the assessment of the MIE. Since most ALI systems work 
with integrated quartz microbalances, they enable quantita-
tive assessment of the deposited dose, which is an important 
aspect of the hazard and risk assessment. Currently, litera-
ture is beginning to become increasingly focused upon this 
research approach, yet there are physiological aspects missing 
from this in vitro next-generation testing strategy that are 
highly pertinent toward their successful combination with 
AOP approaches. Specifically, the addition of lung lining fluid 
compartment, that is, mucus or aqueous lining layer covered 
with surfactant, should be emphasized to mimic the interac-
tion of the NM aerosol with those first barrier. In addition, 
some of the exposure systems are technically challenging and 
time consuming, requiring specific expertise for the produc-
tion of a reproducible aerosol. Also, each cell type and cell 
culture model requires extensive optimization and validation 
under ALI before application for the specific assessment. This 
makes the system low throughput, making the screening sce-
nario much less possible. However, exposure using ALI may 
only be required to evaluate the NM-bio interaction and not 
for the measurement of other KEs in the AOP, which can be 
assessed in submerged conditions.
4.3.2. Cell Type Considerations
There are many characterized primary or immortalized cell 
types derived from lung tissues of rodents and humans, the 
building blocks of the in vitro cell culture systems, available 
(https://www.epithelix.com, https://www.mattek.com/prod-
ucts/epiairway/) and routinely used to construct various in 
vitro models from simple monolayer and advanced multi-cell 
co-culture models to artificial organ constructs that reflect dif-
ferent physiological and anatomical complexity across the dif-
ferent regions of the respiratory system.[84,85] Single cell culture 
models are the most commonly used as they are easy and cheap, 
ready, and ease of access to a variety of cell types from different 
species, including humans, and simplicity of the system.[86] 
These include rat alveolar macrophages (NR8383), SV40 
immortalized mouse alveolar macrophage cell line (MH-S), 
mouse alveolar epithelial adenoma cells (LA-4), human lung 
epithelial type II (“like”) cells (A549), human leukemia mono-
cytic cells (THP-1), and a plethora of others such as the lung 
epithelial cell-line from transgenic MutaMouse (FE-1) that is 
specifically tailored to assess the mutagenic potential of a range 
of chemical substances. Simple co-cultures involving epithelial 
cells and alveolar macrophages[87] or epithelial and endothelial 
cells have become a routine.[88] Adding a layer of complexity, 
more recent models have involved epithelial cells, mac-
rophages, and dendritic cells in a triple cell[89] or epithelial cells, 
macrophages, dendritic cells, and mast cells in a quadruple cell 
type co cultures.[90]
While such models have been useful in assessing the acute 
effects of lung exposure to NM, such as acute oxidative stress 
and inflammation, they are not positioned to assess complex 
pathogenicity such as lung fibrosis, a widely assessed and 
reported AO for NM. The lung fibrosis mechanism described 
in AOP173 involves multiple components including an early 
inflammatory component, a tissue injury component, and the 
tissue regeneration component, all of which involve multiple 
cell types in the lung. Thus, an ideal in vitro lung model must 
include immune cells (e.g., macrophages, dendritic cells) cov-
ering the inflammatory response, type 1 and 2 pneumocytes to 
reproduce damage to the epithelium and fibroblasts to repre-
sent the initiation of proliferation and migration of epithelial 
cells and differentiation of fibroblasts into myofibroblasts, a crit-
ical KE that results in ECM components to repair the damaged 
ACM. The use of fibroblast cultures to assess the release of pro-
fibrotic mediators and ECM components such as fibronectin 
and collagen has been investigated. A study by Vietti and col-
leagues demonstrated the applicability of various fibroblast 
monocultures to induce fibroblast proliferation upon exposure 
to MWCNTs; however, the release of collagen, the building 
blocks of fibrotic lesions, could not be assessed in these mono 
culture systems.[91] More recently, a study by Barosova et al.,[92] 
established a novel tissue construct, that is, the EpiAlveolar 
model, mimicking the lower respiratory tract involving alveolar 
epithelial type I cells, fibroblasts, and endothelial cells that in 
addition to enabling investigation of the acute effects such as 
inflammation, also permit the assessment of chronic effects 
such as barrier integrity and the biological indicators associ-
ated with the onset of lung fibrotic disease. While more simple 
mono-culture systems provide an interesting and easy avenue 
to rapidly assess the toxicity induced by thousands of NM 
variants, the more complex models still need a lot of technical 
skills, time, and money to test a variety of NMs and endpoints.
Whilst long-term efforts continue to close the divide between 
in vivo and in vitro in order to obtain completely replacement 
orientated testing strategies,[93] in the short-term cultures of 
tissues, such as the precision cut lung slice (PCLS) culture 
reflect a good example of a model with next level complexity 
and mimicking an organ response in its entirety.[94] Although a 
considered “refinement” approach to in vivo experimentation, 
since tissue slices can be harvested from any tissue and species 
including humans, the ability to translate data to understanding 
human responses will become more evident. In another recent 
study by Rahman et al.,[95] a lung organ mimic involving PCLS 
culture model, which allows the intricate cellular signaling 
occurring after NM exposure and measurement of various KEs 
along the path of lung fibrosis including the histopathological 
manifestation of the fibrotic disease, was established. Condi-
tional to further optimization, this easy to operate and resource 
effective organoid model offers a promising alternative to 
whole animal testing, significantly reducing the number of ani-
mals required for testing. It enables generation of quality data 
relevant for regulatory assessments. However, they lack a sys-
temic response component that is responsible for recruitment 
of inflammatory cells to the lungs after exposure to NM, which 
is the prime KE node linking all AOPs of relevance of NM inha-
lation exposure (Figure 3). There have been attempts to bridge 
this gap by constructing an organ-on-a-chip or lung-on-a-chip 
model, which not only constitutes essential cell types that are 
involved in orchestrating lung responses to stressors but also 
accurately incorporates the systemic components required for 
the lung response.[96] Whilst efforts continue to bioengineer the 
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human lung in this manner, systems currently available omit 
the important immune cells within the lung,[97] for example, 
macrophages in the alveolar region. Although attempts are 
underway to amend this issue,[98] until it is possible to incorpo-
rate these inflammatory cells, such systems remain unavailable 
for absolute incorporation toward AOP approaches.
5. Putative Adverse Outcome Pathway-Informed 
Animal Reduction and Replacement Strategies  
for Lung Fibrosis
While many in vitro model options are available to choose 
from, it is also realized that no single model is sufficient to use 
in isolation. Thus, a test system that constitutes a combination 
of single cell culture models, co-cultures, tissue constructs, 
and even tissue culture models, is highly recommended to 
accurately predict an in vivo response as relevant to humans. 
The schematic presented in Figure 4 lists three strategies 
involving an ex vivo test system or model constituting the com-
plex lung tissue architecture and all lung cell types, an advance 
in vitro model constituting multiple lung cell types chosen to 
represent the important aspects of lung injury following NM 
exposure and a model constituting different cell types that 
specifically allow separate measurement of early or late KEs 
of the AOP173. All model systems including specific measure-
ments are anchored to AOP173 on lung fibrosis. The strategy 
also highlights that NM deposition techniques or mode of 
exposure can vary across different strategies or within a single 
strategy.
Most test systems, endpoints, and assays identified in this 
review as well as those presented in Figure 5 are well described, 
peer-reviewed, easily transferable, and have experimentally 
demonstrated level of confidence in the results generated, and 
thus are recommended. An ex vivo PCLS method is included in 
this alternative testing strategy even though it involves animal 
experimentation.[95] This is because 1) PCLS uses fewer ani-
mals (four times fewer) to achieve what is traditionally achieved 
in animal experiments. While animal alternatives refer to the 
complete replacement of animals in testing, the PCLS method 
allows significant reduction in the total number of animals 
used, thereby conforms to the reduction philosophy of the 3Rs 
principle. 2) The current regulatory decision making relies on 
animal tissue histopathology results, which establish clinical 
manifestation of a disease that cannot be recapitulated using 
the available in vitro (2D or 3D) techniques. Moreover, in vitro 
cell based models of exposure and assessment are still under 
development, efficiency of which to predict the occurrence of 
an adverse event in vivo is yet to be established. Until that time, 
PCLS technique can play an important role in bridging in vitro 
results with in vivo responses. 3) PCLS technique allows poten-
tial assessment of responses in human tissues, and thus will 
enable establishment of human relevance. For these reasons, 
PCLS method has been included in the strategies shown in 
Figure 5. However, none of the assays are validated formally by 
the prescribed national or international validation standards.
Thus, for now, these assays can be used to serve in an 
early screening tier of toxicity testing. However, to be useful 
in regulatory decision making, in addition to being anchored 
to a mechanism or an AOP, the in vitro assays should also 
be in alignment with the traditional components of the risk 
assessment framework that include hazard identification, 
dose-response characterization, and exposure characteriza-
tion (Figure  5). The selected assays must have been validated 
at the national or international level, which includes evaluation 
of assays and methods for relevance, reliability, specificity. and 
method transferability. However, the caveat for validation is that 
human exposure and effects data are non-existent for NM. For 
example, there is no experimental evidence available to suggest 
that inhalation exposure to NM induces lung fibrosis or res-
piratory diseases in humans. Previously, onsite studies carried 
out in USA, Republic of Korea, Japan, and Europe involving 
research laboratories and both small and large scale production 
facilities, suggested that exposure to NM during their synthesis 
or during accidental spills can occur, especially if exposure-
control measures or safety protocols are not implemented or 
followed. Consumer exposure, although possible, has not been 
well documented (reviewed in Guseva et  al.)[99]. Epidemio-
logical studies involving workers exposed to CNT have found 
increased levels of markers of fibrosis in serum and sputum of 
exposed workers, suggesting that pulmonary inflammation and 
fibrosis to be the likely outcomes in these workers if exposed to 
certain levels and duration. In a recent review article published 
by Schulte et al.,[100] human epidemiological studies of workers 
exposed to nine most widely used NM, including carbon black; 
synthetic amorphous silica; aluminum oxide; barium titanate; 
titanium dioxide, cerium dioxide; zinc oxide; CNT and carbon 
nanofibers; and silver nanoparticles, were systematically evalu-
ated to identify human health effects of exposures to NM. The 
results showed that there is limited evidence to suggest patho-
logical manifestation; however, indicators of adverse effects in 
workers exposed to specific NM (from the nine reviewed in 
this article) have been reported. However, the data on levels 
of NM in environment and biological exposure data, that 
is, biologically available or internal dose is not available, pre-
cluding derivation of dose-response relationships required for 
risk assessments. Similarly, quality animal exposure or effects 
data are scarce for most NM. More importantly, there are no 
accepted benchmark particles against which NM data can be 
compared, which is essential for validation. Alternatively, one 
can use high quality epidemiological studies where available as 
well as chronic and sub-chronic inhalation studies in rodents 
on non-NM particles such as process-generated diesel exhaust 
nanoparticles, or asbestos with abundance of information on 
exposure, hazard, and dose-response relationships, for the pur-
poses of assay validation.[101–105]
6. Next Steps: Considerations for Validation  
and Refinement of Cell Based In Vitro Alternatives
As described earlier, several AOPs of relevance to inhalation 
toxicity of NM are under development; however, only one of 
them (AOP173 for lung fibrosis) is near completion. For the 
rest of AOPs, for now, roadmaps describing putative mecha-
nisms of toxicity exist. Regardless of their development status, 
none of the AOPs are quantitative, suggesting that generation 
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of new data is warranted which will allow their refinement and 
validation of AOPs. Similarly, while specific assays and test 
systems/models for the measurement of the KEs in AOP173 
are identified (Figure  4) and for measuring KEs identified in 
other AOPs, the specific biomolecules (genes, proteins) for tar-
geting by the specific bioassays are still undergoing refinement. 
For example, the KEs of inflammation are mainly assessed by 
the targeted measurement of a select set of pro-inflammatory 
mediators known to be induced by NM,[16] the number and 
types of which vary across the studies, and specific rationale or 
guidance for their selection is not available. This is a critical 
issue and one that will require advanced data mining types 
of approaches involving mathematical and statistical algo-
rithms to address it. For example, high-throughput and high-
content data often referred to as “toxicogenomics” have been 
used in chemical toxicology and nanotoxicology to gain an 
understanding of the toxicity mechanisms and to identify and 
select KEs at all levels of biological organization. The resulting 
dataset consisting of millions of data points has also supported 
validation of MIEs and KEs, and identification of multi-variate 
biomarkers for targeted bioassay development.[26,28,35,95] Such 
gene set- or pathway-based biomarkers are increasingly appli-
cable to diverse predictive modeling approaches in toxicology 
and have been shown to have broad potential for identification 
and probabilistic prediction of human toxicity and AO.[95,106–108] 
Recently establishment and validation of a gene panel con-
sisting of 17 individual genes (Figure  4) potentially predictive 
of lung fibrosis was described in a bioinformatics study by 
Rahman et  al. 2020.[95] The authors showed that the panel of 
17 genes are associated with multiple KEs of the AOP173 for 
lung fibrosis and thus, enable measurement of more than 
one KE in a single assay. Moreover, the study established the 
statistical methodology to derive molecular targets that are 
experimentally validated, anchored to the KEs in the AOP, and 
an experimental test system for their effective measurement. 
Other examples of approaches to identify molecular targets 
associated with specific MIE/KE include bioinformatics-driven 
data integration pipelines aimed at providing bioinformatically 
employable molecular descriptions linked to AOPs[37] (Figure 6, 
left panel). The identification of key biological processes and 
Figure 4. The AOP173 schematic for lung fibrosis and potential animal alternative testing strategies involving combination of exposure models, test 
systems, endpoints, and assays anchored to specific KEs in the AOP. The presented assays and endpoints are experimentally supported and are cur-
rently measured in isolation for assessing individual components of the NM-induced disease mechanisms. Here, how these individual endpoints and 
assays can be combined in a strategic manner to effectively assess NM-induced lung inflammation and fibrosis, is shown. α-SMA - smooth muscle 
actin alpha. TGFb - transforming growth factor beta1. TNF-α - tumour necrosis factor alpha.
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molecular players involved in AOs supports development of 
broad coverage high-content (whole-genome microarray/next 
generation sequencing) and targeted high-throughput tran-
scriptomics (qRT-PCR) assays performed in relevant model sys-
tems[109,110] as described above (Figure  6, middle panels). The 
molecular descriptions serve as multi-variate biomarkers[41] eli-
gible for supporting the development of gene set- or pathway-
based first-tier toxicity testing strategies coupled to probabilistic 
modeling[111] (Figure  6, right panel). In addition, the mole-
cular descriptors can be used to support mechanism-aware 
QSAR approaches.[63,112] This type of molecular descriptors 
have also been used to establish dose-response relationships 
and derive points of departures,[35] useful for ranking of NM 
potency to induce inflammation,[113] identification properties 
responsible for the effects[63] and for prediction of AOs such 
as lung fibrosis.[95] The resulting big data and comprehensive 
knowledge further supports AOP-driven hazard characteriza-
tion, including grouping and read across among substances, 
through implementation of omics-based toxicity prediction 
tools (Figure 6, right panel). Overall, data integration pipelines, 
such as the one described in Figure 6, constantly develop and 
become more automated through diverse efforts between the 
AOP- and the biological pathway-communities. For example, 
some efforts are aiming to allow AOPs to provide an “index” for 
the complexity of the biological pathways in pathway-databases, 
such as WikiPathways.[114] This allows computational scientists 
to dig deeper into the underlying molecular mechanisms out-
lined in the AOPs. The vast amount of data generated can help 
validate the toxicity mechanisms outlined in the AOPs, identify 
new bioassays and new molecular targets for measurement and 
in turn, aid in validation of the bioassays and results (Figure 6, 
feedback arrow from last panel).
7. Conclusion
This review presents the strategies to address the pressing 
need in the community to optimize and validate existing or 
novel animal reduction or replacement alternatives in NM 
toxicity testing; including cell based in vitro, organoid ex vivo 
Figure 5. The role of AOPs in informing various steps of potential HHRA process that is based on alternative testing strategies. The Hazard iden-
tification step of HHRA requires that the biological and toxicity responses are characterized and the underlying toxicity mechanisms are identified. 
AOPs enable the systematic organization of the existing in silico, in vivo, and in vitro data (specific to NM or non-NM data) and serve as mechanistic 
backbones for the establishment of potential animal reduction or replacement strategies. They provide the knowledgebase for the selection of fit for 
purpose in vitro test systems. They aid in the selection of battery of tests for inclusion in an intelligent testing strategy and enable biological interpreta-
tion of the test results. Such mechanisms-founded strategies can then be used to establish dose-response and human relevance. Together with the 
information on material characterization and exposure, indicators of risk can be derived. AOPs can also aid in the selection of NM. For the strategy 
to be successful, it must include NM of varying chemical composition and properties, physicochemical and structural properties of which are well 
characterized. Although, validation of the alternative tests and the resulting information is highly desired, owing to the limited human or animal data, 
it is not clear at present, how that will be achieved. In the interim, where available, in vivo data can be used for validation of the results. In the long 
term, such targeted hazard assessment strategies will reduce the regulatory burden of testing every single NM.
Small 2021, 2007628
2007628 (15 of 20)
www.advancedsciencenews.com
© 2021 Her Majesty the Queen in Right of Canada. Small published by Wiley-VCH GmbH. 
Reproduced with the permission of the Minister of Health Canada
www.small-journal.com
and computational in silico methods, with an expectation that 
these alternatives will eventually help lift the burden placed on 
regulatory agencies to assess an ever growing number of NM 
in a faster, cheaper, and timely manner. The review demon-
strates how the existing literature and more importantly, AOP 
thinking can be used to 1) identify the critical biological events 
(KEs) in the path of an AO, and 2) rationalise testing strategies 
involving combination of exposure models, test systems, end-
points, and assays. By using the existing AOP for lung fibrosis 
as an example, the review recommends combination of specific 
cell or tissue models, assays, and endpoints that can potentially 
be used for predicting in vivo occurrence of lung fibrosis. It is 
acknowledged that some physical chemical properties of NM 
such as solubility are important modifier/predictor of toxicity. 
The AOP example chosen to elaborate in this review concerns 
tissue fibrotic response that mainly originates from persistence 
of an insoluble material and sustained and chronic injury. How-
ever, the mechanism presented and the in vitro testing strate-
gies outlined are also applicable to NM that are highly soluble. 
The proposed strategy is flexible and the individual components 
of it are expected to change as new knowledge and data become 
available. However, for now, the stage is set to embark on the 
new toxicity testing paradigms in nanotoxicology, success of 
which will rely on the active participation of academic, industry, 
and regulatory researchers in adopting the proposed strategies 
for generating and reporting much required toxicity data in a 
consistent manner. This will allow refinement and validation of 
the strategies and expedite the process of drafting of guidance 
documents for their uptake, and application in regulatory deci-
sion making.
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